Lifesci Capital Stock Recommendations and Price Targets

This is a list of recent ratings by Lifesci Capital.

Date	Company Name	Action	Current Price	Price Target	Rating	Impact on Share Price
5/6/2024	CATX Perspective Therapeutics	Reiterated Rating	$2.00		Outperform	N/A
3/26/2024	MLYS Mineralys Therapeutics	Reiterated Rating	$13.00		Outperform	Low
2/28/2024	VTYX Ventyx Biosciences	Upgrade	$5.00		Market Perform ➝ Outperform	Low
2/27/2024	GPCR Structure Therapeutics	Reiterated Rating	$36.00		Outperform	Low
2/20/2024	LRMR Larimar Therapeutics	Reiterated Rating	$7.00		Outperform	Low
1/23/2024	INBX Inhibrx	Downgrade	$35.00		Outperform ➝ Market Perform	Low
1/5/2024	IVA Inventiva	Reiterated Rating	$4.00		Outperform	Low
12/26/2023	TARS Tarsus Pharmaceuticals	Reiterated Rating	$38.00		Outperform	Low
12/26/2023	RCKT Rocket Pharmaceuticals	Reiterated Rating	$23.00		Outperform	Low
12/4/2023	SYRE Spyre Therapeutics	Reiterated Rating	$38.00		Outperform	Low
11/27/2023	TCRX TScan Therapeutics	Reiterated Rating	$9.00		Outperform	Low
11/7/2023	VTYX Ventyx Biosciences	Downgrade	$5.00		Outperform ➝ Market Perform	Low
8/8/2023	TNYA Tenaya Therapeutics	Reiterated Rating	$5.00		Outperform	Low
8/8/2023	INBX Inhibrx	Reiterated Rating	$35.00		Outperform	Low
8/8/2023	VERV Verve Therapeutics	Reiterated Rating	$6.00		Outperform	Low
4/26/2023	OLMA Olema Pharmaceuticals	Reiterated Rating	$10.00		Outperform	Low
4/26/2023	ALXO ALX Oncology	Reiterated Rating	$14.00		Outperform	Low
4/26/2023	AVDL Avadel Pharmaceuticals	Reiterated Rating	$15.00		Outperform	Low
4/26/2023	INBX Inhibrx	Reiterated Rating	$35.00		Outperform	Low
4/26/2023	PYXS Pyxis Oncology	Reiterated Rating	$4.00		Outperform	Low
4/24/2023	IRON Disc Medicine	Reiterated Rating	$32.00		Outperform	Low
4/11/2023	AKRO Akero Therapeutics	Reiterated Rating	$20.00		Outperform	Low
4/5/2023	IFRX InflaRx	Upgrade	$2.00		Market Perform ➝ Outperform	Low
3/31/2023	BTTX Better Therapeutics	Downgrade	$0.00		Outperform ➝ Market Perform	Low
3/27/2023	CRNX Crinetics Pharmaceuticals	Reiterated Rating	$51.00		Outperform	Low
3/8/2023	OBIO Orchestra BioMed	Reiterated Rating	$5.00		Outperform	Low
3/7/2023	ELVN Enliven Therapeutics	Reiterated Rating	$23.00		Outperform	Low
12/21/2022	MLTX MoonLake Immunotherapeutics	Reiterated Rating	$40.00		Outperform	N/A
12/1/2022	PYXS Pyxis Oncology	Reiterated Rating	$4.00		Outperform	Low
11/28/2022	ATXS Astria Therapeutics	Reiterated Rating	$10.00		Outperform	Low
11/8/2022	ALXO ALX Oncology	Reiterated Rating	$14.00		Outperform	Low
9/6/2022	AKLI Akili	Reiterated Rating	$0.00		Outperform	Low
8/12/2022	VYNE VYNE Therapeutics	Downgrade	$3.00		Outperform ➝ Market Perform	Low
8/12/2022	LRMR Larimar Therapeutics	Upgrade	$7.00		Market Perform ➝ Outperform	Low
6/16/2022	TNYA Tenaya Therapeutics	Reiterated Rating	$5.00		Outperform	Low
3/28/2022	VERA Vera Therapeutics	Reiterated Rating	$41.00		Outperform	Low
3/25/2022	ELDN Eledon Pharmaceuticals	Reiterated Rating	$3.00		Outperform	Medium
3/22/2022	LHDXQ Lucira Health	Upgrade	$0.00		Market Perform ➝ Outperform	Low
2/16/2022	LRMR Larimar Therapeutics	Downgrade	$7.00	$3.00	Outperform ➝ Market Perform	Medium
12/27/2021	BTTX Better Therapeutics	Reiterated Rating	$0.00		Outperform	High
12/22/2021	VERV Verve Therapeutics	Reiterated Rating	$6.00		Outperform	High
12/22/2021	ALLK Allakos	Downgrade	$1.00		Outperform ➝ Market Perform	High
11/17/2021	NNOX Nano-X Imaging	Downgrade	$10.00		Outperform ➝ Market Perform	Low
11/15/2021	VTYX Ventyx Biosciences	Reiterated Rating	$5.00		Outperform	High
11/4/2021	ALXO ALX Oncology	Reiterated Rating	$14.00		Outperform	Medium
11/2/2021	PYXS Pyxis Oncology	Reiterated Rating	$4.00		Outperform	Low
10/24/2021	RCKT Rocket Pharmaceuticals	Reiterated Rating	$23.00		Outperform	Low
8/26/2021	DRIO DarioHealth	Reiterated Rating	$2.00		Outperform	High
8/24/2021	VRDN Viridian Therapeutics	Reiterated Rating	$13.00		Outperform	Low
8/13/2021	LHDXQ Lucira Health	Downgrade	$0.00		Outperform ➝ Market Perform	Medium
8/4/2021	LRMR Larimar Therapeutics	Reiterated Rating	$7.00		Outperform	Medium
6/21/2021	OLMA Olema Pharmaceuticals	Reiterated Rating	$10.00		Outperform	High
6/3/2021	NNOX Nano-X Imaging	Reiterated Rating	$10.00		Outperform	High